LG Chem to start developing 'immune checkpoint inhibitors' to treat solid cancer patients
LG Chem to start developing 'immune checkpoint inhibitors' to treat solid cancer patients
  • Cho Eun, Reporter
  • 승인 2024.06.11 15:22
  • 수정 2024.06.11 15:22
  • 댓글 0
이 기사를 공유합니다

Registration as a U.S. Phase 1 clinical trial examiner

Clinical development of immune checkpoint inhibitors will begin in earnest to expand treatment opportunities for solid cancer patients.

LG Chem announced on the 11th that it has registered a test subject in the U.S. phase 1 clinical trial of LB-LR1109 (research task code name LR19155), a new anticancer drug developed by itself.

This candidate is a single antibody drug in the inhibition mechanism of 'LILRB1 (Leukocyte Immunoglobulin Like Receptor B-1).

LILRB1, an immune checkpoint (immune system avoidance) signaling molecule expressed in various immune cells, interferes with the binding of HLA-G (Human Leukocyte antigen-G), a protein that is expressed in cancer cells and prevents immune cells from attacking, and simultaneously activates the functions of the entire immune cells in the body.

There is a distinct difference from existing immune checkpoint inhibitors that focus only on single immune cell action, such as T cells, in that the target protein LILRB1 is commonly expressed on the surface of multiple immune cells such as NK cells (natural killer cells) and macrophages (phagocytosis cells), as well as T cells, which are representative immune cells.

LG Chem plans to recruit patients with advanced or metastatic solid cancer in Korea and the United States to evaluate safety, drug resistance, pharmacokinetics, and pharmacodynamic characteristics.

In addition, in close cooperation with Abeo, an organization specializing in anticancer business, we will establish a strategy for approval of late-stage clinical development.

According to market research firm Global Data, the global market for immune checkpoint inhibitors is expected to continue to expand from 60 trillion won in 2023 to 100 trillion won in 2028.

"We are focusing our company's capabilities on providing innovative treatment experiences recognized and felt by medical staff, patients, and all customers around the world," said Sohn Ji-woong, head of LG Chem's life science business division. "We will continue to present differentiated treatment options in the field of anticancer, which has the greatest demand for medical unmet needs."

[WIKI KOREA=Cho Eun, Reporter]

choeun@wikileaks-kr.org

기자가 쓴 기사

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트